News

01/15/2025 - 16:19

A stable zeolite with atomically ordered and interconnected mesopore channel - Carnot ESP

A revolutionary discovery by the Catalysis & Spectrochemistry Laboratory, a member of the Carnot Energy and Propulsion Systems (ESP), published in Nature Magazine! For the first time, a stable aluminosilicate zeolite with intrinsic mesopores has been designed.

10/07/2024 - 08:37

Discover: Fan-Out Wafer-Level Packaging - CEA-Leti

CEA-Leti offers a competitive Fan-Out Wafer-Level Packaging technology using 8” wafers. Based on the reconstruction of substrates around individual chips, this technology has become an iconic part of any “More than Moore” strategy. This advanced technology has enabled high-potential, multi-chip system-in-packages since the mid-2000s. 
Eliminating the need for intermediate, laminated substrates has enabled the integration of high performance systems with a reduced cost and footprint. It has also paved the way for applications that would have been difficult to address using conventional packaging.

07/18/2024 - 13:30

Technology to enhance the relationship between the elderly and their pets

As they get older, the elderly are often forced to give up owning a pet, despite the benefits of such a relationship. What if technology could help preserve this precious bond? This could potentially slow down the loss of autonomy.  This is the subject of Hazar Zilelioglu's thesis, which brings together academic and industrial partners, with the support of Carnot TSN.

07/09/2024 - 13:42

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, today announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results. This second part ot the Phase I study is evaluating PEP-010 in combination with chemotherapy (paclitaxel or gemcitabine), in advanced or metastatic ovarian cancer (OC) and in metastatic pancreatic ductal adenocarcinoma (PDAC), two indications with high unmet medical need.

06/20/2023 - 18:40

Phenomenon of shrinkage and swelling of clayey soils (RGA): definitions, impacts on structures and people and solutions for adaptation to climate change

Under the effects of climate change, weather events are becoming more frequent and intense in terms of loss experience and damage costs. Lightweight structures such as houses and houses and roads, built on very plastic clay soils and sensitive to the shrinkage and swelling phenomena, suffer more degradations due to drought.
The Cerema, Institut Carnot Institute Clim'adapt, works and mobilizes those concerned to develop new remedial solutions to reduce the vulnerability of buildings exposed to the RGA and its resilience to climate change.

02/03/2022 - 16:15

Robust blockchains for the financial markets

Clearmatics Technologies develops blockchain-based solutions for the financial markets. The company turned to Carnot CEA LIST Institute for support developing solutions that meet the unique needs of financial transactions.

02/03/2022 - 16:09

Advances in high-performance photonic chips

Carnot CEA Leti Institute has been developing photonics on silicon nitride for several years now. Today, the technology is mature enough to address growing demand for high-performance chips. 

03/25/2021 - 10:54

New technology enables safer surgical training

Today, medical students can practice surgical procedures on "digital doubles" of patients in a safe, controlled virtual reality environment. When combined with haptic interfaces (from the Greek word haptomai, meaning "touch"), these tools can rapidly bring interns up to speed for clinical examinations on real patients.

03/25/2021 - 10:41

COVID-19: Institut Imagine and Cerba HealthCare are partnering to test for patients likely to develop severe symptoms

In 2020, researchers at Inserm, Université de Paris, and Assistance Publique–Hôpitaux de Paris (AP-HP), in collaboration with the university hospital organisation Institut Imagine (Hôpital Necker-Enfants malades AP-HP), which has been granted “Institut Carnot” certification through The Rockefeller University and the Howard Hughes Medical Institute in New York, identified the leading genetic and immunological causes responsible for at least 15% of serious forms of Covid-19. Today, this same French and American team, jointly lead by Jean-Laurent Casanova and Laurent Abel* at the Institut Imagine and The Rockefeller University, is joining forces with Cerba HealthCare, a leading stakeholder in medical diagnostics, to transform these discoveries into clinical applications and screen individuals who are more likely to develop a severe form of the disease and tailor their treatment accordingly.

11/09/2018 - 13:16

Earth System and Big Data : Launch of the European Infrastructure EPOS

Wednesday 7 November 2018 officially launches the European Plate Observing System (EPOS) for the pooling of data and services for the study of our planet. BRGM Carnot Institute is part of this initiative.